Penumbra Tops $410M Revenue, Up 15.6%, But Suspends Guidance on Boston Scientific Deal
PEN sits 46% above its 52-week low of $221.26 on elevated volume (2.0× avg).
Summary
Penumbra posted Q3 2026 revenue of $410.1 million, up 15.6% from a year ago, with thrombectomy sales of $279.2 million up 18.1% and U.S. VTE revenue up 26.0%. Gross margin improved to 68.3% and net income came in at $42.3 million, or $1.07 per diluted share, versus $45.9 million a year earlier. Operating expenses rose to $229.6 million, including $7.1 million of acquisition-related costs tied to the pending Boston Scientific takeover. Because that deal is pending, Penumbra gave no full-year 2026 guidance and skipped its earnings call, so the print stands on its own without forward commentary. The revenue beat direction and strong thrombectomy growth matter most for PEN holders; BSX is the acquirer and sees the same numbers through the lens of the pending deal.
At the time of this announcement, PEN was trading at $321.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.7B. The 52-week trading range was $221.26 to $362.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.